Inhaled formoterol during one year in asthma: a comparison with salbutamol. 1991

P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
Dept of Pulmonary Medicine, University of Göteborg, Sweden.

Eighteen patients, who had previously taken part in a 2 wk cross-over comparison between formoterol and salbutamol, now took part in a one year double-blind study comparing salbutamol 200 micrograms b.i.d. with formoterol 12 micrograms b.i.d. Additional doses were taken when needed and were recorded. Ten patients were started on formoterol and eight on salbutamol. After one month, the patients were allowed to shift to the alternative drug. Two patients withdrew from the study. At the end of the study, 13 of 16 patients were on formoterol, thus showing a long-lasting preference for this drug. Forced expiratory volume in one second (FEV1) dose-response curves for inhaled salbutamol were repeatedly recorded during the study, and no tachyphylaxis was found. One patient stopped taking inhaled steroids but continued taking formoterol and theophylline. He deteriorated with a decreased response to salbutamol. After re-introduction of inhaled steroids his condition improved. This case indicates that effective bronchodilator therapy may mask the deterioration of asthma.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010366 Peak Expiratory Flow Rate Measurement of the maximum rate of airflow attained during a FORCED VITAL CAPACITY determination. Common abbreviations are PEFR and PFR. Expiratory Peak Flow Rate,Flow Rate, Peak Expiratory,PEFR
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004983 Ethanolamines AMINO ALCOHOLS containing the ETHANOLAMINE; (-NH2CH2CHOH) group and its derivatives. Aminoethanols
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
June 2002, Respiratory medicine,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
August 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
July 1998, Saudi medical journal,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
January 1994, The Indian journal of chest diseases & allied sciences,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
January 2004, Pulmonary pharmacology & therapeutics,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
May 1985, Australian paediatric journal,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
January 2002, Pulmonary pharmacology & therapeutics,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
July 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
October 2012, Pulmonary pharmacology & therapeutics,
P Arvidsson, and S Larsson, and C G Löfdahl, and B Melander, and N Svedmyr, and L Wåhlander
March 2012, BMC pediatrics,
Copied contents to your clipboard!